Details of the ocular surface evaluation of study group and control group
| Study groups | Mean BCVA±SD (range) | Mean IOP±SD (range) mm Hg | Mean TBUT±SD (range) (s) | Mean Schirmer’s I test±SD (range) (mm) | Mean corneal staining score±SD (range) | Mean conjunctival staining score±SD (range) | Dry eye severity level |
| Group I (antiglaucoma medication with BAK) | |||||||
| Group I A Timolol with BAK (n=22 eyes) | 0.51±0.37 (0–1) | 17.36±3.27 (12–24) | 6.79±1.47 (5.03–9.78) | 11.97±7.08 (5–13) | 3.25±1.01 (2–5) | 6.79±1.47 (5.03–9.78) | 2 |
| Group I B Timolol+PG with BAK (n=36 eyes) | 0.38±0.32 (0–1) | 16.05±4.57 (8–24) | 6.79±1.50 (5.03–11.09) | 11.97±7.23 (5–35) | 3.25±1.10 (2–6) | 6.79±1.50 (5.03–11.09) | 2 |
| Group I C PG with BAK (n=24 eyes) | 0.49±0.30 (0–1) | 17.96±3.37 (12–23) | 6.79±1.50 (5.03–8.99) | 11.97±7.23 (5–23) | 3.25±1.10 (2–6) | 6.79±1.50 (5.03–8.99) | 2 |
| Total (n=82) | 0.44±0.33 (0–1) | 16.96±3.96 (8–24) | 6.65±1.58 (3–11.09) | 11.97±7.23 (4–35) | 3.30±1.17 (2–7) | 6.65±1.58 (3–11.09) | 2 |
| Group II (antiglaucoma medication without BAK) | |||||||
| Group II A Timolol without BAK (n=14 eyes) | 0.36±0.34 (0–0.9) | 18.07±3.41 (12–23) | 7.01±1.39 (5.21–9.09/1.39) | 13.16±7.58 (4–14) | 3.17±0.86 (2–4) | 5.98±1.27 (3–7) | 1 |
| Group II B Timolol+PG without BAK (n=13 eyes) | 0.46±0.28 (0–0.78) | 18.54±6.91 (12–40) | 6.95±1.38 (5.12–10.0) | 13.36±7.78 (7–30) | 3.24±0.88 (2–4) | 5.90±1.26 (4–7/1.26) | 1 |
| Group II C PG without BAK (n=44 eyes) | 0.41±0.34 (0–1) | 17.91±3.46 (10–25) | 6.95±1.38 (5.02–9.65) | 13.14±7.60 (4–35) | 3.19±0.86 (2–6) | 1.28±1.28 (4–9) | 1 |
| Total (n=71) | 0.41±0.33 (0–1) | 18.06±4.21 (10–40) | 6.88±1.54 (3–10.01) | 13±7.62 (3–35) | 3.32±1.22 (2–9) | 6±1.27 (2–9) | 1 |
| Group III (controls) | |||||||
| Control eyes (n=30) | 0±0 (0–0) | 15.73±2.40 (12–21) | 13.51±1.41 (10.99–15.91) | 32.33±2.03 (29–35) | 0 | 0 | 0 |
| P values | |||||||
| *P value (group I vs group II) | – | 0.324 | 0.72 | 1.0 | 0.29 | 0.60 | – |
| *P value (group I vs control) | – | 0.331 | 0.00 | 0.00 | – | – | – |
| *P value (group II vs control) | – | 0.018 | 0.00 | 0.00 | – | – | – |
One-way analysis of variance/ Kruskal-Wallis test followed by multiple comparisons, Bonferroni/Dunn’s test with Bonferroni correction.
BAK, benzalkonium chloride; BCVA, best corrected visual acuity; IOP, intraocular pressure; PG, preservative group; TBUT, tear breakup time.